Form 8-K - Current report:
SEC Accession No. 0000950170-24-096641
Filing Date
2024-08-14
Accepted
2024-08-14 07:00:08
Documents
13
Period of Report
2024-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K igms-20240814.htm   iXBRL 8-K 40622
2 EX-99.1 igms-ex99_1.htm EX-99.1 151417
3 GRAPHIC img140404641_0.jpg GRAPHIC 3792
  Complete submission text file 0000950170-24-096641.txt   325012

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT igms-20240814.xsd EX-101.SCH 25963
15 EXTRACTED XBRL INSTANCE DOCUMENT igms-20240814_htm.xml XML 4937
Mailing Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043
Business Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043 650-965-7873
IGM Biosciences, Inc. (Filer) CIK: 0001496323 (see all company filings)

EIN.: 770349194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39045 | Film No.: 241204064
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)